Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Aldeyra (ALDX) rises 43% in one week, driven by plans to initiate a pivotal study to support the resubmission of reproxalap NDA for dry eye disease in the first half of 2024.
Here is how Aclaris Therapeutics (ACRS) and Aldeyra Therapeutics, Inc. (ALDX) have performed compared to their sector so far this year.
0957 ET – Overhang on GSK shares from litigation surrounding the heartburn drug Zantac is likely to diminish after peer Sanofi agreed in principle to settle thousands of claims in the U.S., Barclays analysts say in a note. Sanofi’s agreement to settle claims around allegations that Zantac caused cancer is positive, indicating GSK will also seek settlements, they say. “We believe that we’re highly unlikely to see any Zantac case go to trial with either GSK or Sanofi as a named defendant,” the a...
Aldeyra Therapeutics surges 15% to $4.10, following an upgrade from Oppenheimer citing the company's development plan for resubmitting a New Drug Application [NDA] for its dry eye disease treatment reproxalap. In a report, Analyst Francois Brisebois raises Aldeyra to outperform from perform with a $10 price target. Brisebois says he believes "recent clarity from the FDA gives a path forward for reproxalap with initiation of [a} derisked symptom trial for [dry eye disease] in 1H24 followed by N...
Aldeyra Therapeutics, Inc. ( NASDAQ:ALDX ) is possibly approaching a major achievement in its business, so we would...
LEXINGTON, Mass., March 28, 2024--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the clinical development plan intended to enable resubmission of a New Drug Application (NDA) of topical ocular 0.25% reproxalap, an investigational RASP modulator, for the treatment of dry eye disease to the U.S. Food and Drug Administration (FDA). Follow
Todd Brady, President and CEO of Aldeyra Therapeutics Inc (NASDAQ:ALDX), has sold 183,238 shares of the company on March 12, 2024, according to a recent SEC Filing.
Here, we discuss some reasons why investing in Aldeyra Therapeutics (ALDX) stock now may turn out to be a prudent move.
Here is how Aclaris Therapeutics (ACRS) and Aldeyra Therapeutics, Inc. (ALDX) have performed compared to their sector so far this year.
United Therapeutics, Esperion Therapeutics., Heron Therapeutics, Lyra Therapeutics and Aldeyra Therapeutics are part of the Zacks Industry Outlook article.